42.99
+0.3(+0.70%)
Currency In USD
| Previous Close | 42.69 |
| Open | 42.76 |
| Day High | 43.7 |
| Day Low | 42.47 |
| 52-Week High | 43.7 |
| 52-Week Low | 29.16 |
| Volume | 672,632 |
| Average Volume | 775,561 |
| Market Cap | 2.41B |
| PE | 37.38 |
| EPS | 1.15 |
| Moving Average 50 Days | 34.39 |
| Moving Average 200 Days | 34.55 |
| Change | 0.3 |
If you invested $1000 in Supernus Pharmaceuticals, Inc. (SUPN) 10 years ago, it would be worth $2,463.61 as of August 18, 2025 at a share price of $42.99. Whereas If you bought $1000 worth of Supernus Pharmaceuticals, Inc. (SUPN) shares 5 years ago, it would be worth $1,716.17 as of August 18, 2025 at a share price of $42.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
GlobeNewswire Inc.
Jul 31, 2025 12:44 PM GMT
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and furth
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
GlobeNewswire Inc.
Jul 28, 2025 12:25 PM GMT
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvem
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
GlobeNewswire Inc.
Jul 22, 2025 8:30 PM GMT
ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announ